Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes-Reference-Cited by-同舟云学术

Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes

Published:2021-06-23 Issue:5 Volume:27 Page:751-759
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Sun Haowei (Linda)¹^ORCID,Yang Ming²^ORCID,Poon Man‐Chiu³^ORCID,Lee Adrienne³,Robinson K. Sue⁴,Sholzberg Michelle⁵,Wu John⁶,Iorio Alfonso⁷^ORCID,Blanchette Victor⁸,Carcao Manuel⁸^ORCID,Klaassen Robert J.⁹,Jackson Shannon²¹⁰

Affiliation:

1. Division of Hematology Department of Medicine University of Alberta Edmonton Alberta Canada

2. British Columbia Hemophilia Treatment Centre ‐ Adult Division Vancouver British Columbia Canada

3. Department of Medicine Foothills Medical Centre, Cumming School of Medicine University of Calgary Calgary Alberta Canada

4. Division of Hematology Department of Medicine University of Dalhousie Halifax Nova Scotia Canada

5. Division of Hematology Departments of Medicine and Laboratory Medicine & Pathobiology St. Michael's Hospital Toronto Ontario Canada

6. Division of Hematology Oncology British Columbia Children and Women's Hospital Vancouver British Columbia Canada

7. Division of Hematology Department of Medicine McMaster University Hamilton Ontario Canada

8. Department of Pediatrics, Division of Hematology/Oncology, The Hospital for Sick Children University of Toronto Toronto Ontario Canada

9. Division of Hematology Oncology Department of Pediatrics Children's Hospital of Eastern Ontario Research Institute Ottawa Ontario Canada

10. Division of Hematology Department of Medicine University of British Columbia Vancouver British Columbia Canada

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14369

Reference11 articles.

1. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

2. Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

3. WFH Guidelines for the Management of Hemophilia, 3rd edition [published online ahead of print, 2020 Aug 3];Srivastava A;Haemophilia,2020

4. Regional variation and cost implications of prescribed extended half‐life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany;Research and Practice in Thrombosis and Haemostasis;2024-07

2. Recombinant factor IX Fc for the treatment of hemophilia B;European Journal of Haematology;2024-02-18

3. Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A;European Journal of Haematology;2023-10-24

4. Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand;Research and Practice in Thrombosis and Haemostasis;2023-08

5. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B;Blood Advances;2023-06-30